Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
February 2016, Vol 7, No 1
February 2016, Vol 7, No 1
Value-Based Care Must Be Linked to Improved Clinical Outcomes
By
James T. Kenney, RPh, MBA
Economics & Value
,
Payer’s Perspective
,
Value-Based Care
,
Value Peer-spectives
February 2016, Vol 7, No 1
Society meetings, such as the recent American Society of Hematology (ASH) annual meeting, generate a lot of clinical-related excitement regarding new treatment options, protocols, and pathways for hematologic cancers.
Read Article
CAR T-Cell Therapy Highly Active in Various Lymphomas
Hematologic Malignancies
,
Lymphoma
February 2016, Vol 7, No 1
The use of therapy with chimeric antigen receptor (CAR)-modified T-cells consistently demonstrated activity in advanced hematologic malignancies, including different types of lymphoma, in multiple trials reported at ASH 2015.
Read Article
Venetoclax Shows Strong Activity in CLL
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
February 2016, Vol 7, No 1
The oral, investigational, small-molecule BCL-2 inhibitor venetoclax has shown excellent and durable responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). All patients in the trial harbored the 17p deletion (del 17p), which signals poor prognosis.
Read Article
Checkpoint Inhibitors in Lymphoma: A New Universe
By
Phoebe Starr
Hematologic Malignancies
,
Immunotherapy
,
Lymphoma
,
Personalized Medicine
February 2016, Vol 7, No 1
Immunotherapy is generating great excitement in melanoma and non-small-cell lung cancer (NSCLC). The FDA approvals of checkpoint inhibitors in these tumor types, as well as encouraging preliminary results in other solid tumors, have paved the way for studying these therapies in hematologic cancers.
Read Article
Immunotherapy with Blinatumomab Prolongs Survival in Acute Lymphoblastic Leukemia
By
Chase Doyle
Hematologic Malignancies
,
Leukemia
February 2016, Vol 7, No 1
Treatment with CD19-targeted immunotherapy blinatumomab (Blincyto) as a single agent showed antileukemic activity in patients with minimal residual disease (MRD) Philadelphia chromosome (Ph)-positive B-cell precursor acute lymphoblastic leukemia (ALL) whose disease progressed after or was intolerant to a second-generation or later tyrosine kinase inhibitor (TKI). The results were presented at ASH 2015.
Read Article
Ibrutinib a New Standard of Care for Elderly Patients with Chronic Lymphocytic Leukemia
By
Phoebe Starr
Hematologic Malignancies
,
Leukemia
February 2016, Vol 7, No 1
Ibrutinib (Imbruvica) significantly reduced the risk for disease progression or death compared with standard treatment with chlorambucil (Leukeran) in older (aged ≥65 years) treatment-naive patients with chronic lymphocytic leukemia (CLL). Ibrutinib achieved a 91% reduction in the risk for disease progression and an 84% reduction in the risk for death compared with chlorambucil.
Read Article
Idelalisib Improves Survival When Added to Bendamustine plus Rituximab in Patients with CLL
By
Phoebe Starr
Hematologic Malignancies
,
Leukemia
February 2016, Vol 7, No 1
Idelalisib (Zydelig) reduced the risk for disease progression and death when added to bendamustine (Treanda) plus rituximab (Rituxan) versus bendamustine plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to the results of a randomized, double-blind, placebo-controlled, phase 3 late-breaking trial presented at ASH 2015.
Read Article
Nilotinib Yields Better Rates of Molecular Response Than Imatinib in Frontline Setting
By
Chase Doyle
Hematologic Malignancies
,
Leukemia
February 2016, Vol 7, No 1
Dose-optimized nilotinib (Tasigna) increased the rates of major molecular response in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase (CP) in the Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Extending Molecular Responses (ENESTxtnd) study. According to the final results of this study presented at ASH 2015, the cumulative major molecular response rates were 70.8% by 12 months and 81.0% by 24 months in patients managed with the dose optimization strategy.
Read Article
Daratumumab Improves Overall Survival in Multiple Myeloma
By
Dana Taylor
Hematologic Malignancies
,
Multiple Myeloma
February 2016, Vol 7, No 1
With the accelerated FDA approval in December 2015 of the anti-CD38 monoclonal antibody daratumumab (Darzalex) for patients with multiple myeloma who received ≥3 previous therapies, studies of the drug presented at ASH 2015 were of great interest.
Read Article
Consistent Benefit Over Time in Elotuzumab Studies
By
Dana Taylor
Hematologic Malignancies
,
Multiple Myeloma
February 2016, Vol 7, No 1
The immunostimulatory monoclonal antibody elotuzumab (Empliciti), which was approved by the FDA in December 2015, is being studied in combination with immunomodulatory drugs and proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Results presented at ASH 2015 show continued benefit from these regimens.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma